Veracyte sets November 4 results date for Veracyte stock

Published on 10/15/2026 at 12:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 150.3 million, up 15 percent year over year. Veracyte stock costs EUR 38.85 on October 15, 2026.

Dated results and clinical evidence

Veracyte scheduled its third-quarter results for November 4, 2026.
The second-quarter transcript reported USD 150.3 million of revenue and 15 percent growth on July 30, 2026.
Veracyte stock was trading at EUR 38.85 at Lang & Schwarz on October 15, 2026 at 12:42 p.m. CEST.
The Decipher analysis covered 395 patients and showed an 8 percent reduction at 10 years on September 29, 2026.

VCYT, US92337F1075, Illustration mit AI erstellt.

Veracyte (ISIN US92337F1075) scheduled its third-quarter 2026 financial results for November 4, 2026, with management set to host a conference call at 4:30 p.m. Eastern Time, according to Stockwatch on October 14, 2026. The date gives investors the next scheduled test of Veracyte's growth and profitability.

Revenue set the latest benchmark

Yahoo Finance reported that Veracyte generated USD 150.3 million of revenue in the second quarter of 2026, up 15 percent from the same period of 2025. The company also reported 48,389 testing procedures during the quarter, while adjusted EBITDA reached USD 44.0 million, equal to 29.2 percent of revenue.

The same July 30, 2026 earnings call said Veracyte raised its full-year 2026 revenue guidance to USD 590 million to USD 596 million from USD 582 million to USD 592 million. The new range represents 14 percent to 15 percent year-over-year growth and puts the November report against a higher company target.

Three dated milestones

On July 30, 2026, Veracyte reported USD 150.3 million of second-quarter revenue. On September 25, 2026, the company announced eight Decipher-focused studies for presentation at ASTRO 2026, as listed on its investor-relations page. On September 29, 2026, Veracyte reported phase III findings showing an 8 percent absolute reduction in distant metastasis at 10 years for patients with intermediate or high Decipher scores who received short-term hormone therapy with radiation.

What does the evidence add?

The September analysis covered 395 patients from the NRG/RTOG 0815 trial, with a median follow-up of 10.2 years. Among patients with low Decipher scores, representing 44 percent of the biomarker group, the absolute difference in distant metastasis was 1 percentage point and was not statistically significant. That contrast gives the test's clinical evidence a more specific role than a broad treatment signal.

Next date for investors

The next scheduled corporate event is the third-quarter results release on November 4, 2026, after the market close, followed by the 4:30 p.m. Eastern Time conference call. Veracyte's primary listing is Nasdaq under ticker VCYT, and its business centers on molecular diagnostics for cancer care.

Stock quote in euros

Veracyte stock was trading at EUR 38.85 at Lang & Schwarz on October 15, 2026 at 12:42 p.m. CEST. The current euro quote gives German investors a dated market reference ahead of the company's November results.

The further course of trading is shown by the continuously updated real-time quote of Veracyte stock.